ID   CCK-81 R2 Cetux
AC   CVCL_A2BU
SY   CCK81 R2 Cetux
DR   cancercelllines; CVCL_A2BU
DR   Cosmic; 2841358
DR   Wikidata; Q105506588
RX   PubMed=25623215;
CC   Population: Japanese.
CC   Selected for resistance to: DrugBank; DB00002; Cetuximab (Erbitux).
CC   Sequence variation: Mutation; HGNC; HGNC:16712; FBXW7; Simple; p.Arg465Cys (c.1393C>T); ClinVar=VCV000376414; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; HGNC:8975; PIK3CA; Simple; p.Cys420Arg (c.1258T>C); ClinVar=VCV000031945; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; HGNC:11998; TP53; Simple; p.Pro278His (c.833C>A); ClinVar=VCV000376646; Zygosity=Heterozygous (from parent cell line).
CC   Derived from site: Metastatic; Lymph node; UBERON=UBERON_0000029.
DI   NCIt; C4349; Colon adenocarcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_2873 ! CCK-81
SX   Female
AG   62Y
CA   Cancer cell line
DT   Created: 12-01-21; Last updated: 19-12-24; Version: 7
//
RX   PubMed=25623215; DOI=10.1158/1078-0432.CCR-14-2821;
RA   Arena S., Bellosillo B., Siravegna G., Martinez A., Canadas I.,
RA   Lazzari L., Ferruz N., Russo M., Misale S., Gonzalez I., Iglesias M.,
RA   Gavilan E., Corti G., Hobor S., Crisafulli G., Salido M., Sanchez J.,
RA   Dalmases A., Bellmunt J., De Fabritiis G., Rovira A.,
RA   Di Nicolantonio F., Albanell J., Bardelli A., Montagut C.;
RT   "Emergence of multiple EGFR extracellular mutations during cetuximab
RT   treatment in colorectal cancer.";
RL   Clin. Cancer Res. 21:2157-2166(2015).
//